Particle.news

Download on the App Store

University of Geneva Identifies Protein Gatekeepers for Targeted Cancer Therapies

Next steps include testing whether these proteins can be targeted to kill cancer cells

Image

Overview

  • Researchers used CRISPR-Cas9 screening of more than 20,000 genes to uncover MLF2 and RBM15 as critical regulators of chromatin remodeling.
  • MLF2 and RBM15 act as gatekeepers that control chromatin accessibility and gene expression, safeguarding cellular identity and preventing aberrant activation linked to cancer and neurodevelopmental disorders.
  • The findings, published in Nature Communications, reveal how these proteins integrate with the SWI/SNF complex to modulate chromatin dynamics.
  • Targeting MLF2 and RBM15 may enable more selective and less toxic treatments by restoring proper chromatin architecture.
  • Researchers will next evaluate whether inhibiting these proteins can kill tumor cells and are screening for molecules that correct chromatin dysfunctions.